141 related articles for article (PubMed ID: 30487243)
1. Targeted Therapy for EBV-Associated B-cell Neoplasms.
Ganguly S; Kuravi S; Alleboina S; Mudduluru G; Jensen RA; McGuirk JP; Balusu R
Mol Cancer Res; 2019 Apr; 17(4):839-844. PubMed ID: 30487243
[TBL] [Abstract][Full Text] [Related]
2. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.
Suarez-Kelly LP; Kemper GM; Duggan MC; Stiff A; Noel TC; Markowitz J; Luedke EA; Yildiz VO; Yu L; Jaime-Ramirez AC; Karpa V; Zhang X; Carson WE
Oncotarget; 2016 Dec; 7(49):81172-81186. PubMed ID: 27783987
[TBL] [Abstract][Full Text] [Related]
3. Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma.
Ravi D; Beheshti A; Abermil N; Passero F; Sharma J; Coyle M; Kritharis A; Kandela I; Hlatky L; Sitkovsky MV; Mazar A; Gartenhaus RB; Evens AM
Cancer Res; 2016 Jun; 76(11):3319-31. PubMed ID: 26988986
[TBL] [Abstract][Full Text] [Related]
4. A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas.
Boonstra PS; Polk A; Brown N; Hristov AC; Bailey NG; Kaminski MS; Phillips T; Devata S; Mayer T; Wilcox RA
Am J Hematol; 2017 Dec; 92(12):1287-1294. PubMed ID: 28842936
[TBL] [Abstract][Full Text] [Related]
5. A New Perspective for Osteosarcoma Therapy: Proteasome Inhibition by MLN9708/2238 Successfully Induces Apoptosis and Cell Cycle Arrest and Attenuates the Invasion Ability of Osteosarcoma Cells in Vitro.
Liu R; Fu C; Sun J; Wang X; Geng S; Wang X; Zou J; Bi Z; Yang C
Cell Physiol Biochem; 2017; 41(2):451-465. PubMed ID: 28214890
[TBL] [Abstract][Full Text] [Related]
6. The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib.
Engür S; Dikmen M
Acta Clin Belg; 2017 Dec; 72(6):391-398. PubMed ID: 28327055
[TBL] [Abstract][Full Text] [Related]
7. Small molecule growth inhibitors of human oncogenic gammaherpesvirus infected B-cells.
Dzeng RK; Jha HC; Lu J; Saha A; Banerjee S; Robertson ES
Mol Oncol; 2015 Feb; 9(2):365-76. PubMed ID: 25306391
[TBL] [Abstract][Full Text] [Related]
8. Wogonin as a targeted therapeutic agent for EBV (+) lymphoma cells involved in LMP1/NF-κB/miR-155/PU.1 pathway.
Wu X; Liu P; Zhang H; Li Y; Salmani JM; Wang F; Yang K; Fu R; Chen Z; Chen B
BMC Cancer; 2017 Feb; 17(1):147. PubMed ID: 28222771
[TBL] [Abstract][Full Text] [Related]
9. Cell cycle arrest induced by engagement of B7-H4 on Epstein-Barr virus-positive B-cell lymphoma cell lines.
Park GB; Song H; Kim YS; Sung M; Ryu JW; Lee HK; Cho DH; Kim D; Lee WJ; Hur DY
Immunology; 2009 Nov; 128(3):360-8. PubMed ID: 20067536
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of duvelisib on Epstein-Barr virus-associated lymphoma cells.
Kawada JI; Ando S; Torii Y; Watanabe T; Sato Y; Ito Y; Kimura H
Cancer Med; 2018 Apr; 7(4):1275-1284. PubMed ID: 29522278
[TBL] [Abstract][Full Text] [Related]
11. An HIV protease inhibitor, ritonavir targets the nuclear factor-kappaB and inhibits the tumor growth and infiltration of EBV-positive lymphoblastoid B cells.
Dewan MZ; Tomita M; Katano H; Yamamoto N; Ahmed S; Yamamoto M; Sata T; Mori N; Yamamoto N
Int J Cancer; 2009 Feb; 124(3):622-9. PubMed ID: 18973272
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis.
Pham LV; Tamayo AT; Yoshimura LC; Lo P; Ford RJ
J Immunol; 2003 Jul; 171(1):88-95. PubMed ID: 12816986
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells.
Augello G; Modica M; Azzolina A; Puleio R; Cassata G; Emma MR; Di Sano C; Cusimano A; Montalto G; Cervello M
Cell Death Dis; 2018 Jan; 9(2):28. PubMed ID: 29348495
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.
Zou P; Kawada J; Pesnicak L; Cohen JI
J Virol; 2007 Sep; 81(18):10029-36. PubMed ID: 17626072
[TBL] [Abstract][Full Text] [Related]
15. A mechanistic insight into a proteasome-independent constitutive inhibitor kappaBalpha (IkappaBalpha) degradation and nuclear factor kappaB (NF-kappaB) activation pathway in WEHI-231 B-cells.
Shumway SD; Miyamoto S
Biochem J; 2004 May; 380(Pt 1):173-80. PubMed ID: 14763901
[TBL] [Abstract][Full Text] [Related]
16. Constitutive activation of distinct NF-κB signals in EBV-associated nasopharyngeal carcinoma.
Chung GT; Lou WP; Chow C; To KF; Choy KW; Leung AW; Tong CY; Yuen JW; Ko CW; Yip TT; Busson P; Lo KW
J Pathol; 2013 Nov; 231(3):311-22. PubMed ID: 23868181
[TBL] [Abstract][Full Text] [Related]
17. Cell-cycle regulators, bcl-2 and NF-kappaB in Epstein-Barr virus-positive gastric carcinomas.
Chang MS; Lee HS; Jung EJ; Kim CW; Lee BL; Kim WH
Int J Oncol; 2005 Nov; 27(5):1265-72. PubMed ID: 16211221
[TBL] [Abstract][Full Text] [Related]
18. Curcumin improves the antitumor effect of X-ray irradiation by blocking the NF-κB pathway: an in-vitro study of lymphoma.
Qiao Q; Jiang Y; Li G
Anticancer Drugs; 2012 Jul; 23(6):597-605. PubMed ID: 22273827
[TBL] [Abstract][Full Text] [Related]
19. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
[TBL] [Abstract][Full Text] [Related]
20. Role of di-allyl disulfide, a garlic component in NF-κB mediated transient G2-M phase arrest and apoptosis in human leukemic cell-lines.
Dasgupta P; Bandyopadhyay SS
Nutr Cancer; 2013; 65(4):611-22. PubMed ID: 23659453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
